Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 162 recruiting now early-phase tilt #14 of 28,707 conditions

Colorectal Cancer: early-phase trial registry

162 of 394 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #14 of 28,707 conditions by registered trial count.

394 US clinical trials · 162 currently recruiting · #14 of 28,707 conditions by registered trial count

Colorectal Cancer: 394 US clinical trials tracked, 162 recruiting.

Colorectal Cancer is the subject of 394 registered US clinical trials on ClinicalTrials.gov, 162 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 201 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.

Enrollment posture brief

Registry condition colorectal-cancer

OPEN 162 | RECR 41% | LATE 13 | EARLY 201 | RANK #14 | SPON 22

Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)

Heart Failure41.1%Colorectal Cancer (this)41%Anxiety40.3%Pain28.1%Asthma18.5%
Open-enrollment share among volume-matched conditions near Colorectal Cancer

Colorectal Cancer lists 162 open slots (41% of 394 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Cancer is recruiting above its size-band peers.

    162 of 394 indexed trials (41.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 22 of 394 trials (5.6%). 222 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Cancer enrolment sits around 132 participants.

    Median target enrolment is 132 among the 382 trials that report a genuine target (sentinel values excluded). 162 of those (42.4%) plan for fewer than 100 participants.

  4. Colorectal Cancer research is mostly interventional.

    323 interventional and 71 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1132Phase 269Phase 310Phase 43

Open and recent trials

394 total, page 7 of 8

COMPLETED Phase 2 76 participants

Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption

University of Florida

NCT06137248

COMPLETED Phase 1 73 participants

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Pfizer

NCT04672460

COMPLETED Phase 2 70 participants

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

SCRI Development Innovations

NCT01490866

COMPLETED 70 participants

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

University of Kansas Medical Center

NCT00442520

COMPLETED Phase 2 70 participants

Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)

Bayer

NCT04126733

COMPLETED Phase 2 67 participants

Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer

Hoffmann-La Roche

NCT00022698

COMPLETED Phase 2 66 participants

5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer

SCRI Development Innovations

NCT00308516

COMPLETED Phase 1 64 participants

Oral STAT3 Inhibitor, TTI-101, in Patients with Advanced Cancers

Tvardi Therapeutics, Incorporated

NCT03195699

COMPLETED NA 63 participants

Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool

Indiana University

NCT01803009

COMPLETED NA 62 participants

Initial Testing of a Mobile App Pain Coping Intervention for Outpatient Oncology Settings (PainPac)

Duke University

NCT05686122

COMPLETED NA 60 participants

Shared Decision-making and Colorectal Cancer Screening

Abramson Cancer Center at Penn Medicine

NCT04748380

COMPLETED NA 57 participants

Motivational Interviewing for Colonoscopy

Icahn School of Medicine at Mount Sinai

NCT01877096

COMPLETED NA 57 participants

Colonoscope Insertion Trial Protocol

UConn Health

NCT01324882

COMPLETED Phase 2 54 participants

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

OHSU Knight Cancer Institute

NCT00381862

COMPLETED Phase 1 54 participants

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Incyte Corporation

NCT04580485

COMPLETED Phase 2 53 participants

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

University of Colorado, Denver

NCT03475004

COMPLETED NA 51 participants

Preoperative 3D Models and Shared Decision-making

Vanderbilt University Medical Center

NCT06625008

COMPLETED Phase 1 51 participants

Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors

Akamis Bio

NCT02636036

COMPLETED NA 50 participants

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

SWOG Cancer Research Network

NCT01453452

COMPLETED Phase 1 50 participants

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

David Bajor, MD

NCT02861300

COMPLETED Phase 1 49 participants

Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer

Medical University of South Carolina

NCT00003344

COMPLETED Phase 1 48 participants

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

NCT01451632

COMPLETED Phase 1 48 participants

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences

NCT03629756

COMPLETED Phase 1 48 participants

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

Celldex Therapeutics

NCT00709462

COMPLETED 47 participants

Biomarkers in Patients With Rectal Cancer Undergoing Chemotherapy and Radiation Therapy

UNC Lineberger Comprehensive Cancer Center

NCT00280761

COMPLETED Phase 1 47 participants

RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

University of Utah

NCT01047293

COMPLETED Phase 1 45 participants

Study of KCC Peptide Application in the Colon

Danielle Kim Turgeon

NCT02156557

COMPLETED Phase 2 45 participants

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

NYU Langone Health

NCT00005049

COMPLETED Phase 2 44 participants

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

Academic Thoracic Oncology Medical Investigators Consortium

NCT03542877

COMPLETED Phase 1 44 participants

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

PureTech

NCT04666688

COMPLETED NA 43 participants

Colonoscopy Screening: Setting Epic Follow-up Times

Massachusetts General Hospital

NCT05631873

COMPLETED Phase 1 42 participants

A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer

Genentech

NCT00671372

COMPLETED Phase 1 42 participants

Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

Syndax Pharmaceuticals

NCT05731947

COMPLETED NA 42 participants

e-Motivación: Developing and Pilot Testing an App to Improve Latinos' Screening Colonoscopy Rates

Icahn School of Medicine at Mount Sinai

NCT04987788

COMPLETED Phase 2 40 participants

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

St. Vincent Medical Center - Los Angeles

NCT00002475

COMPLETED Phase 1 40 participants

Curcumin Biomarkers

University of North Carolina, Chapel Hill

NCT01333917

COMPLETED NA 40 participants

Energy Balance Interventions for Colorectal Cancer Prevention

Vanderbilt University

NCT00653484

COMPLETED Phase 1 39 participants

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Bristol-Myers Squibb

NCT00441337

COMPLETED Phase 2 38 participants

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Rutgers, The State University of New Jersey

NCT01006369

COMPLETED Phase 1 38 participants

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Tempest Therapeutics

NCT03829436

COMPLETED Phase 2 36 participants

Cetuximab Plus Biweekly Capecitabine and Oxaliplatin in KRAS Wild Type Metastatic Colorectal Cancer

NYU Langone Health

NCT00444678

COMPLETED Phase 2 35 participants

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Memorial Sloan Kettering Cancer Center

NCT03693807

COMPLETED Phase 2 34 participants

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

M.D. Anderson Cancer Center

NCT01730586

COMPLETED Phase 2 32 participants

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

AstraZeneca

NCT01116271

COMPLETED NA 32 participants

Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)

M.D. Anderson Cancer Center

NCT02613728

COMPLETED Phase 1 32 participants

Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver

MediGene

NCT00149396

COMPLETED Phase 2 30 participants

A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer

OncoNano Medicine

NCT03735680

COMPLETED NA 30 participants

Engaging Black Men in Colorectal Cancer Screening

Virginia Commonwealth University

NCT05980182

COMPLETED Phase 1 29 participants

A Study of a Personalized Neoantigen Cancer Vaccine

Gritstone bio

NCT03639714

COMPLETED NA 29 participants

Pain Coping Skills for Colorectal Cancer Survivors

Duke University

NCT02706301

← Previous Page 7 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 132
Phase 2 69
Phase 3 10
Phase 4 3

Named interventions

Most-linked intervention names on Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Drug
15 trials
Oxaliplatin Drug
14 trials
Bevacizumab Drug
11 trials
irinotecan hydrochloride Drug
9 trials
fluorouracil Drug
9 trials
Irinotecan Drug
9 trials
leucovorin calcium Drug
8 trials
Leucovorin Drug
7 trials

US sites by state

Facility locations filed on Colorectal Cancer trials. A trial with sites in several states counts in each.

California 133 trials
New York 100 trials
Texas 98 trials
Florida 86 trials
Massachusetts 64 trials
Pennsylvania 57 trials
Tennessee 53 trials
Michigan 51 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colorectal Cancer page

394 registered trials, 162 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer condition card totals 394 registered trials; most-linked intervention Cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.